Related Experiment Videos
Update on basic research and clinical experience with metaiodobenzylguanidine
1Division of Nuclear Medicine, University of Michigan Medical Center, Ann Arbor 48109.
Medical and Pediatric Oncology
|January 1, 1987
Summary
I 131-metaiodobenzylguanidine (MIBG) imaging effectively detects adrenal and extra-adrenal pheochromocytomas, even when other scans are normal. This nuclear medicine technique also aids in staging neuroblastoma and shows promise for treating malignant forms.
Area of Science:
- Nuclear Medicine
- Oncology
- Radiopharmacology
Background:
- I 131-metaiodobenzylguanidine (MIBG) shares structural similarities with norepinephrine (NE), leading to its concentration, storage, and release from chromaffin granules like NE.
- MIBG imaging can identify enlarged adrenal medullae in adrenal medullary hyperplasia when CT and MRI scans are inconclusive.
Purpose of the Study:
- To evaluate the efficacy of I 131-metaiodobenzylguanidine (MIBG) in imaging and potentially treating neuroendocrine tumors, specifically pheochromocytomas and neuroblastomas.
- To compare the sensitivity of MIBG imaging with conventional methods like CT and MRI for detecting pheochromocytomas.
Main Methods:
- Utilized I 131-metaiodobenzylguanidine (MIBG) as a radiotracer for imaging patients with pheochromocytomas and neuroblastomas.
- Compared MIBG imaging results with histopathological findings and outcomes from CT and MRI scans.
- Administered MIBG for therapeutic purposes in patients with malignant pheochromocytomas and tracked treatment responses.
Main Results:
- MIBG imaging demonstrated higher sensitivity in detecting extra-adrenal pheochromocytomas compared to CT and MRI.
- Annual MIBG imaging is recommended for patients with histopathologically proven "benign" pheochromocytomas due to a significant rate of metastasis (46%).
- MIBG imaging proved valuable in staging neuroblastoma, sometimes revealing more tumor extent than other modalities. Objective tumor regressions (30-50%) were observed in 3 of 12 neuroblastoma patients treated with MIBG.
Conclusions:
- I 131-metaiodobenzylguanidine (MIBG) is a sensitive imaging agent for pheochromocytomas and neuroblastomas, outperforming CT and MRI in certain cases.
- MIBG imaging plays a crucial role in the management of pheochromocytomas, including surveillance for metastasis and staging of neuroblastoma.
- The therapeutic potential of MIBG in malignant neuroendocrine tumors warrants further investigation, as evidenced by observed tumor regressions.